Ignite Creation Date:
2024-07-17 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06476964
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-19
Brief Title:
Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic Metabolic and Inflammatory Characteristics
Sponsor:
University Hospital Bordeaux
Organization:
University Hospital Bordeaux
Study Overview
Official Title:
Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic Metabolic and Inflammatory Characteristics
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
StratiKA
Brief Summary:
A collection of biological samples skin will be created to meet the objectives Skin biopsies will be taken excluding on face and fold in accordance with standard practice
Detailed Description:
Skin cancers are the most common type of cancer in human Among them cutaneous squamous cell carcinomas cSCCs represent the 2nd most frequent with an incidence that continues to grow 300 between 1994 and 2006 in line with the ageing of the population and sun exposure habits cSCCs is a multi-stage carcinogenesis model the pre-cancerous lesion is actinic keratosis AK which can either regress or progressively evolve into cSCC in situ and then infiltrating and in some patients into a metastatic stage initially lymph node and then distant life-threatening cSCCs are classified as low-risk or high-risk according to clinical and histological criteria associated with the risk of recurrence and metastasis However there is currently no tool for predicting this risk for a given cSCC particularly according to its genetic characteristics Indeed the high mutation rate makes it difficult to identify specific genetic profiles Similarly there is no tool to predict the potential for a precancerous lesion AK to regress or to develop into a cSCC The aim of this study is to characterize the molecular and metabolic features as well as immunologic landscapes of precancerous AK and cSCCs in order to uncover epithelial and immune cell subpopulations supporting tumor progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None